Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 6/20 | 0.43 |
| ▸ | CCNB2 | O95067 | 5/20 | 0.43 |
| ▸ | CDK1 | P06493 | 5/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.43 |
| ▸ | CCNB3 | Q8WWL7 | 5/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 5/20 | 0.43 |
| ▸ | CDK5R1 | Q15078 | 5/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | DRD4 | P21917 | 2/20 | 0.40 |
| ▸ | DRD3 | P35462 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.37 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.37 |
| ▸ | AHR | P35869 | 2/20 | 0.36 |
| ▸ | CMA1 | P23946 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | GSK3A | P49840 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3484049 | 0.84 | AHR (0.40) | EGFRERBB2GSK3BCCNB2CDK1 | |
| SCHEMBL3483928 | 0.81 | KMT2A (0.51) | EGFRERBB2GSK3BCCNB2CDK1 | |
| SCHEMBL3484676 | 0.80 | AHR (0.56) | EGFRERBB2GRIA1CACNG8AHR | |
| SCHEMBL3484800 | 0.79 | — | — | |
| SCHEMBL7678812 | 0.77 | ALDH1A1 (0.43) | GSK3BCCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL3484778 | 0.77 | PGR (0.38) | EGFRERBB2HPGD | |
| SCHEMBL3484612 | 0.74 | MAOB (0.50) | EGFRERBB2GRIA1CACNG8AHR | |
| SCHEMBL3484543 | 0.74 | EGFR (0.49) | EGFRERBB2CDK1CDK5HPGD | |
| SCHEMBL3484884 | 0.74 | EIF2AK2 (0.62) | EGFRERBB2DRD2AHRCMA1 | |
| SCHEMBL3484409 | 0.74 | HPGD (0.50) | HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| CN-101611041-A | Condensed heterocyclic compouds | TAKEDA PHARMACEUTICAL (JP) | 2009-12-23 | — | — | CN | disclosed |
| EP-2103620-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | ERBB2, ROS1, FLT3 | EGFR 13/4885ERBB2 1/4885GSK3B 1568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.